Nina Rawal, Trill Impact Ventures, on the investment in Cinclus Pharma
Highlights from the 2024 Annual Report: Interview with Nina Rawal. Trill Impact Ventures views Cinclus Pharma as a strong Life Science candidate with the potential to address unmet medical needs in GERD and H. pylori. Nina Rawal, Co-Head of Ventures and a board member at Cinclus Pharma, contributes her biomedical expertise and financing experience.
Read more
